In the current study, we observed that in the tumor tissue, APE1 protein, an essential DNA repair enzyme in the BER pathway, could be a promising predictive biomarker for the responses of NSCLC patients receiving platinum-containing chemotherapy. The gene discussed is APEX1; the disease is neoplasm.